Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sam Chun Dang Pharm Co Ltd
Common Stock
Sam Chun Dang Pharm Co Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Common Stock
₩11.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Yuhan Corp
KRX:000100
|
Common Stock
₩81.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Common Stock
₩39.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Common Stock
₩32B
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
M
|
Mezzion Pharma Co Ltd
KOSDAQ:140410
|
Common Stock
₩15.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
28%
|
CAGR 10-Years
14%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Common Stock
₩5.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Sam Chun Dang Pharm Co Ltd
Glance View
Sam Chun Dang Pharm Co Ltd is a quintessential tale of innovation and resilience in the ever-evolving pharmaceutical landscape. Founded in 1943, this South Korean company has steadily crafted its way into becoming a significant player in the generic drug market. Initially focusing on traditional herbal remedies, the company astutely shifted its focus towards the production of generic drugs, capitalizing on the increasing demand for cost-effective alternatives to branded medications. Sam Chun Dang's business model pivots on manufacturing and distributing a wide range of pharmaceutical products, including prescription drugs, over-the-counter medicines, and active pharmaceutical ingredients, catering to both domestic and international markets. The company thrives by meticulously investing in research and development, ensuring a robust pipeline of new generics ready for market entry as patents on branded drugs expire. By emphasizing quality and affordability, Sam Chun Dang Pharm Co Ltd leverages its state-of-the-art manufacturing facilities, accredited by international standards, to maintain a competitive edge. Their profitability stems from not only their comprehensive product lineup but also strategic partnerships and collaborations that enhance their market penetration. Despite operating within a highly competitive and regulated industry, Sam Chun Dang’s commitment to consistent quality and innovation helps them sustain revenue growth and solidify their position as a reputable pharmaceutical provider.
See Also
What is Sam Chun Dang Pharm Co Ltd's Common Stock?
Common Stock
11.7B
KRW
Based on the financial report for Dec 31, 2025, Sam Chun Dang Pharm Co Ltd's Common Stock amounts to 11.7B KRW.
What is Sam Chun Dang Pharm Co Ltd's Common Stock growth rate?
Common Stock CAGR 10Y
1%
Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Sam Chun Dang Pharm Co Ltd have been 1% over the past three years , 1% over the past five years , and 1% over the past ten years .